drugset / Trial / NCT00970073
Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
RandomizedParallel-groupOpen-labelPrevention
Summary
This study will evaluate the use of a drug called Thymoglobulin, combined with a delayed start of the anti-rejection drugs (10 days after liver transplant), compared to the current approach of starting anti-rejection drugs called calcineurin inhibitors or CNI's within 2 days after the liver transplant.
Timeline
- Start
- 2009-08
- Primary completion
- 2015-06-15
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tacrolimus | Small molecule | — | — |
| Subject | Thymoglobulin | Protein / enzyme biologic | 3 mg/kg | — |
| Subject | Thymoglobulin | Protein / enzyme biologic | 4.5 mg/kg | — |
| Background | Mycophenolate Mofetil | Small molecule | 1000 mg | Oral |
Indications
No indication recorded.